No takes yet. Share an insight, caveat, or question.
Systematic review demonstrates that CGM can differentiate glucose levels in prediabetes and normoglycemia, indicating its potential use in risk assessment.
These results provide the first quantitative evidence that CGM can discriminate between prediabetes and normoglycemia, supporting its potential as a complementary tool for refined metabolic risk assessment. Further prospective studies are needed to determine its predictive value for progression to T2DM.
Rákóczi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: